# A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

> **NCT04635527** · PHASE1 · TERMINATED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 10 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** IBI318
- **PROCEDURE:** cTACE
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04635527
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-24
- **Primary completion:** 2021-08-27
- **Final completion:** 2023-03-07
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Due to the company's development strategy adjustment ，Innovent Bioligics decided not to continue the study after consultation with investigators.
- **Last updated:** 2023-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04635527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04635527, "A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04635527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*